Abstract

Hemodialysis-related-heparin-induced thrombocytopenia (HD-HIT) is a drug-induced, immunoglobulin- mediated disorder that it is suspected in dialysis patients with an unexpected fall in the platelet count, and/or unexplained thrombotic events, particularly visible clotting in the circuit under an adequate heparin dose, that begins between 5 and 10 days (nadir between 7 and 30 days, mostly by the third to fifth session) after heparin initiation. Although a positive result for anti-PF4/heparin complex antibodies (HIT antibodies) is presumably detected by sensitive ELISA, the diagnosis should be confirmed, whenever possible, using a functional assay. Immediately after the clinical suspicion of HIT, all sources of heparin should be discontinued including heparin used to flush or lock catheters. Alternative non-heparin anticoagulants, preferentially a direct thrombin inhibitor, should be restarted for dialysis. Early treatment is important as thrombus formation including a clotting circuit may complicate at a high rate within 30 days after the cessation of heparin. Argatroban, a synthetic direct thrombin inhibitor, as an alternative to heparin, must contribute to the rapid recovery of the platelet count and disappearance of visible circuit clotting. A steady decreasing of the ELISA titers can be expected after heparin discontinuation. A negative seroconversion of HIT antibodies is usually observed by ~30 to more than 100 days after discontinuation. Re-exposure to heparin can be selected at the same dose of heparin as used before the onset of HIT. A small peak of HIT antibodies may often appear after exposure, but a follow-up of the antibody titers shows that they not reach a threshold to induce the recurrence of HIT. When HD-HIT patients exhibit a high index of thrombotic formation or worsening thrombosis, the same alternative anticoagulant therapy may be needed on non-session days.

Highlights

  • Unfractionated heparin is the most commonly used anticoagulant for hemodialysis (HD) [1]

  • Heparin may contribute to HDassociated platelet activation, thrombocytopenia, and increased platelet factor 4 (PF4) release from platelets during a heparin dialytic session [2]

  • When a diagnosis of heparin-induced thrombocytopenia (HIT) based on clinical symptoms of thrombocytopenia and immunoassay for PF4/heparin complex antibodies is employed, it remains unclear why a few patients develop HIT

Read more

Summary

Introduction

Unfractionated heparin (heparin) is the most commonly used anticoagulant for hemodialysis (HD) [1]. When a diagnosis of HIT based on clinical symptoms of thrombocytopenia and immunoassay for PF4/heparin complex antibodies is employed, it remains unclear why a few patients develop HIT. There are two kinds of dialysis-related complication: unexpected clotting in the circuit, and abrupt fistula thrombosis. The former seems to be more frequent in HIT than that in non-HIT patients. A few patients showed the effective resolution of clotting and a slow increase of the platelet count to the baseline level in a subsequent session receiving nafamostat mesilate, no clinical trial has ever been carried out to evaluate the efficacy in the management of HIT [8]. Tends to appear in an early session after starting HD with heparin, some patients with the PF4/heparin complex antibody may have a risk of delayed-onset HIT

Frequency of HIT in dialysis patients
Clotting circuit
Cardiovascular surgery in patients with chronic hemodialysis
AVF thrombus
Findings
Characteristics of acute systemic reaction in dialytic patients

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.